|
|
Volumn 103, Issue 20, 2011, Pages 1493-1494
|
|
Enthusiasm for antibody - Drug conjugates
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBODY CONJUGATE;
ANTINEOPLASTIC AGENT;
BRENTUXIMAB VEDOTIN;
DOCETAXEL;
GEMTUZUMAB OZOGAMICIN;
INOTUZUMAB OZOGAMICIN;
TRASTUZUMAB;
TRASTUZUMAB EMTANSINE;
AMINOGLYCOSIDE;
CAC10 VCMMAE;
CAC10-VCMMAE;
DRUG DERIVATIVE;
GEMTUZUMAB;
MAYTANSINE;
MONOCLONAL ANTIBODY;
TRASTUZUMAB DM1 CONJUGATE;
TRASTUZUMAB-DM1 CONJUGATE;
ACUTE GRANULOCYTIC LEUKEMIA;
BREAST CANCER;
CANCER CHEMOTHERAPY;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CELL KILLING;
CONFERENCE PAPER;
DRUG APPROVAL;
DRUG MARKETING;
DRUG SAFETY;
FOOD AND DRUG ADMINISTRATION;
HODGKIN DISEASE;
HUMAN;
LARGE CELL LYMPHOMA;
PRIORITY JOURNAL;
PROGRESSION FREE SURVIVAL;
SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA;
TREATMENT OUTCOME;
NOTE;
PHASE 3 CLINICAL TRIAL (TOPIC);
AMINOGLYCOSIDES;
ANTIBODIES, MONOCLONAL, HUMANIZED;
ANTINEOPLASTIC AGENTS;
CLINICAL TRIALS, PHASE III AS TOPIC;
DRUG APPROVAL;
HUMANS;
IMMUNOCONJUGATES;
MAYTANSINE;
|
|
EID: 84856401825
PISSN: 00278874
EISSN: 14602105
Source Type: Journal
DOI: 10.1093/jnci/djr422 Document Type: Conference Paper |
|
Times cited : (7)
|
|
References (0)
|
